Abstract: The present invention relates to a process for the preparation of canagliflozin and intermediates thereof.

Abstract: The present invention provides a process for the preparation of linagliptin, a compound of Formula I, the process comprising deprotecting a compound of Formula II wherein R1 and R2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phthalimido group is substituted with one or more R3 substituents selected from the group consisting of halogen, alkyl, nitro and amino; or R1 is H and R2 is selected from the group consisting of trialkylsilyl, 2-trialkylsilylethoxycarbamates, acetyl, trihaloacetyl, 9-fluorenylmethoxycarbonyl, trityl, alkylsulfonyl, arylsulfonyl, diphenylphosphine and sulfonylethoxycarbonyl.

Abstract: The present invention provides a process for the preparation and purification of apixaban.

Abstract: The present invention provides process for the preparation of ivacaftor and solvates thereof.

Abstract: The present invention provides a process for the preparation of linagliptin, a compound of Formula I, the process comprising deprotecting a compound of Formula II wherein R1 and R2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phthalimido group is substituted with one or more R3 substituents selected from the group consisting of halogen, alkyl, nitro and amino; or R1 is H and R2 is selected from the group consisting of trialkylsilyl, 2-trialkylsilylethoxycarbamates, acetyl, trihaloacetyl, 9-fluorenylmethoxycarbonyl, trityl, alkylsulfonyl, arylsulfonyl, diphenylphosphine and sulfonylethoxycarbonyl.

Abstract: Provided is a process for the preparation of linagliptin of Formula I, comprising deprotecting a compound of Formula II wherein R1 and R2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phthalimido group is substituted with one or more R3 substituents selected from the group consisting of halogen, alkyi, nitro and amino; or R1 is H and R2 is selected from the group consisting of trialkylsilyl, 2-trialkylsilylethoxycarbamates, acetyl, trihaloacetyl, 9-fluorenylmethoxycarbonyl, trityl, alkylsulfonyl, arylsulfonyl, diphenylphosphine and sulfonylethoxycarbonyl.

Abstract: The present invention provides process for the preparation of ivacaftor and solvates thereof.

Abstract: The present invention provides a process for the preparation and purification of apixaban.

Abstract: Provided is a process for the preparation of linagliptin of Formula I, comprising deprotecting a compound of Formula II wherein R1 and R2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phthalimido group is substituted with one or more R3 substituents selected from the group consisting of halogen, alkyi, nitro and amino; or R1 is H and R2 is selected from the group consisting of trialkylsilyl, 2-trialkylsilylethoxycarbamates, acetyl, trihaloacetyl, 9-fluorenylmethoxycarbonyl, trityl, alkylsulfonyl, arylsulfonyl, diphenylphosphine and sulfonylethoxycarbonyl.

Abstract: Systems and methods for blade health monitoring are provided. According to one embodiment of the disclosure, a system may include a feature extraction module and an anomaly detection module in communication with the extraction module. The feature extraction module may be configured to continuously receive blade passing signal data associated with clearance of a blade and pre-process the blade passing signal data. Blade clearance feature data may be extracted from the blade passing signal data prior to transmission to the anomaly detection module. The anomaly detection module may be configured to normalize the blade clearance feature data received from the extraction module, analyze the blade clearance feature data to detect a shift in the clearance of the blade, and determine an abnormality of the blade based on the shift exceeding a predetermined shift threshold.

Abstract: The present invention relates to amorphous form of bazedoxifene acetate and a process for the preparation thereof.

Abstract: The present invention provides a process for production of an anticancer taxoid brevifoliol of the formula I from plants belonging to the genus Taxus by first extracting the dried and pulverized leaves of the plant with an alcohol preferably at a temperature in the range of 20-40° C. and then. concentrating the solvent to obtain an alcoholic extract. The alcoholic extract obtained is then adsorbed with an adsorbent and the resulting adsorbed material is then dried at a temperature ranging from 20-50° C. for 4-48 hours. The dried adsorbed material is then extracted with a combination of an aliphatic solvent and a chlorinated solvent successively and concentrated to obtain a residue. The residue is subjected to gross fractionation using column chromatography such as silica gel, florosil and silicic acid followed by chromatography with a suitable adsorbent to get brevifoliol.

Abstract: The present invention provides a process for production of an anticancer taxoid brevifoliol of the formula I from plants belonging to the genus Taxus by first extracting the dried and pulverized leaves of the plant with an alcohol preferably at a temperature in the range of 20-40° C. and then. concentrating the solvent to obtain an alcoholic extract. The alcoholic extract obtained is then adsorbed with an adsorbent and the resulting adsorbed material is then dried at a temperature ranging from 20-50° C. for 4-48 hours. The dried adsorbed material is then extracted with a combination of an aliphatic solvent and a chlorinated solvent successively and concentrated to obtain a residue. The residue is subjected to gross fractionation using column chromatography such as silica gel, florosil and silicic acid followed by chromatography with a suitable adsorbent to get brevifoliol.

Abstract: Frovatriptan succinate substantially in an amorphous form is disclosed. Also disclosed is a composition comprising frovatriptan succinate in a solid form, wherein at least about 80% by weight of the solid is frovatriptan succinate in an amorphous form. The present invention also provides a process for preparing frovatriptan succinate substantially in an amorphous form by providing a solution of frovatriptan succinate in one or more solvents capable of dissolving the frovatriptan succinate and substantially removing the solvent from the solution.

Abstract: The present invention relates to the bioactivity of taxanes isolated from the leaves of Himalayan Yew tree Taxus wallichiana against human cancer cell lines grown in-vitro and subsequent identification of brevifoliol [1] as anticancer agent useful in the treatment of various types of cancer in humans

Abstract: Demethylation of 3?, 4?-dimethoxy or 3?, 4?, 5?-trimethoxy benzoic ester of a phenol is carried out in the presence of an excess of aluminum halide in an organic solvent to get 4?-Hydroxy, 3?-methoxy or 4? hydroxy, 3?, 5?-dimethoxy benzoic acid ester of a phenol. The reaction is also applicable to 3?, 4?, 5?-trimethoxy diaryl ketone and some natural products like reserpine.

Abstract: Demethylation of 3?,4?-dimethoxy or 3?,4?,5?-trimethoxy benzoic ester of a phenol is carried out in the presence of an excess of aluminum halide in an organic solvent to get 4?-Hydroxy, 3?-methoxy or 4? hydroxy, 3?,5?-dimethoxy benzoic acid ester of a phenol. The reaction is also applicable to 3?,4?,5?-trimethoxy diaryl ketone and some natural products like reserpine.

Abstract: The present invention relates to a pharmaceutical composition useful as a hepatoprotective agent, said composition comprising of a mixture of coumarinolignoids of formula 1,2 and 3. The present invention also relates to a improved process for production of liver protective composition containing coumarinolignoids of formula 1, 2 and 3 from Cleome viscosa with optimized ratios of the same. More particularly, the present invention relates to a processing technology for the isolation of a combination of coumarinolignoids Cliv-92 comprising a mixture of coumarinolignoids of formula 1,2 and 3 from the seeds of Cleome viscosa.

Abstract: The present invention provides a process for production of an anticancer taxoid brevifoliol of the formula 1 1

Abstract: The present invention relates to the bioactivity of taxanes isolated from the leaves of Himalayan Yew tree Taxus wallichiana against human cancer cell lines grown in-vitro and subsequent identification of brevifoliol [1] as anticancer agent useful in the treatment of various types of cancer in humans.